Shionogi Of Japan, GSK Of U.K. Report Good Results From HIV/AIDS Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Shionogi reports strong encouragement from Phase II trials for its drug to treat HIV/AIDS. Shionogi is testing the drug as part of a joint development deal with GlaxoSmithKline of the United Kingdom. Their study indicated the S/GSL1349572 drug lowered the virus to levels that could not be detected in 70 percent of the participants. After 10 days, none of the South Africa patients displayed drug resistance, the study said. The drug relies on blocking the integrase enzyme. (Click here for more